Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome.

Autor:	Skaudickas D; Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50161, Kaunas, Lithuania., Telksnys T; Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50161, Kaunas, Lithuania., Veikutis V; Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania., Aniulis P; Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50161, Kaunas, Lithuania., Jievaltas M; Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50161, Kaunas, Lithuania.
Jazyk:	angličtina
Zdroj:	Open medicine (Warsaw, Poland) [Open Med (Wars)] 2020 Jul 01; Vol. 15 (1), pp. 580-585. Date of Electronic Publication: 2020 Jul 01 (Print Publication: 2020).
DOI:	10.1515/med-2020-0174
Abstrakt:	Background: Prostatitis is the most commonly diagnosed disease in men younger than 50 years and accounts for about 8% of all urologists' consultations. Objective: After evaluating clinical trials and demonstrating the efficacy of chronic non-bacterial prostatitis treatment, it remains of clinical importance to continue studies on the use of low-energy extracorporeal shock wave therapy (ESWT) in men. Materials and Methods: From May 2017 to April 2018, 40 patients with chronic prostatitis (CP) type IIIB/chronic pelvic pain syndrome (CPPS) were enrolled in the study. The patients underwent ESWT once a week for 4 weeks. Results: The mean age of the patients was 47.8 years. A statistically significant improvement in all the parameters, i.e., the International Prostate Symptom Score (IPSS), the visual analogue scale (VAS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and the International Index of Erectile Function (IIEF), was observed at week 4. The effect of the treatment was maintained during the entire 12-week period. The NIH-CPSI total score showed the best improvement at week 4, but a slight deterioration without a statistically significant change was noticed at week 12. The greatest improvement at week 4 was documented for the NIH-CPSI and IPSS (43% and 37%, respectively). At week 12, an improvement of 52% and 39% was recorded for VAS and IPSS, respectively. Conclusions: Our findings confirmed the effectiveness and safety of ESWT in resistant cases of CPPS in the short term. ESWT is cost-effective, which takes little time or requires a small amount of staff, and is easily conducted. Competing Interests: Conflicts of interest: Authors state no conflict of interest. (© 2020 Darijus Skaudickas et al., published by De Gruyter.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu